GE HealthCare Technologies, the medical‑imaging arm of General Electric, is reportedly in advanced discussions to acquire Sofie Biosciences for roughly $1 billion. The potential transaction, first reported by the Financial Times, would add a leading radiopharmaceutical developer to GE HealthCare’s growing diagnostics portfolio.
Why the deal matters
Sofie Biosciences specializes in producing radioisotopes for positron emission tomography (PET) scans, particularly agents that help detect gastro‑oesophageal and pancreatic cancers. By bringing Sofie’s capabilities in‑house, GE HealthCare aims to strengthen its supply chain for the chemicals and agents that power cancer‑diagnostic imaging across the United States and abroad.
Timing and background
According to the report, the companies could announce the deal as soon as next week. This would be GE HealthCare’s second major acquisition since it separated from General Electric in the three‑way corporate split of 2024, underscoring the company’s aggressive push to expand its presence in the pharmaceutical‑diagnostics market.
Impact on the industry
Industry analysts note that consolidating radiopharmaceutical production can improve reliability for hospitals and imaging centers that depend on timely delivery of PET tracers. A unified supply chain may also reduce costs for patients and insurers, aligning with broader goals of making advanced cancer diagnostics more accessible.
Company statements
Both GE HealthCare and Sofie Biosciences were not immediately reachable for comment outside regular business hours. Reuters could not independently verify the report at the time of publication.
Looking ahead
If the acquisition proceeds, GE HealthCare will likely integrate Sofie’s research and manufacturing capabilities into its existing diagnostics division, potentially accelerating the development of new PET imaging agents. The move reflects a continued trend of large health‑technology firms investing in specialized biotech firms to broaden their service offerings.
Stakeholders will be watching for regulatory review outcomes and any further details on how the combined entity plans to leverage Sofie’s technology to improve cancer detection and treatment planning.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
